Immune and inflammation confusion in severe sepsis and effects of bi-immunomodulation therapy: A prospective, randomized, controlled clinical trial

National Medical Journal of China

Volumn 89, Issue 15, 2009, Pages 1028-1033

  Zhou, Li Xin ^a   Tan, Jia Ju ^b   Li, Yi Nan ^b   Luo, Hong Tao ^b   Shao, Yong Hong ^b   Qiang, Xin Hua ^b   Yu, Tie Ou ^b   Ma, Ming Yuan ^b   Mao, Ke Jiang ^b   Fang, Bin ^b  

^a THE FIRST PEOPLE S HOSPITAL OF FOSHAN   (China)

^b NONE

Author keywords

Continuous blood purification; Immunity; Inflammation; Randomized controlled trials; Sepsis; Thymosin

Indexed keywords

CD14 ANTIGEN; HLA DR ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 6; THYMOSIN ALPHA1; TUMOR NECROSIS FACTOR ALPHA;

ADSORPTION; ADULT; ARTICLE; ARTIFICIAL VENTILATION; BLOOD SAMPLING; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; CONTINUOUS RENAL REPLACEMENT THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; HUMAN; IMMUNOMODULATION; IMMUNOPATHOLOGY; IMMUNOTHERAPY; INFLAMMATION; INTENSIVE CARE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MORTALITY; PROTEIN BLOOD LEVEL; PURIFICATION; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SURVIVAL RATE;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HEMOFILTRATION; HUMANS; IMMUNITY, CELLULAR; INFLAMMATION; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; SEPSIS; THYMOSIN;

EID: 77954785982     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0376-2491.2009.15.006     Document Type: Article

References (22)

1. Nalanson C, Esposito CJ, Banks SM. The sirens' songs of confirmatory sepsis trials: selection bias and sampling error. Crit Care Med, 1998,26:1927-1931.
2. Weighardt H, Heidecke CD, Emmanuilidis K, et al. Sepsis after major visceral surgery is associated with sustained and interferony resistant detects of monocyte cytokine production. Surgery, 2000,127:309-313
3. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/KSICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med, 2003,311:250-256.
4. Dellinger RP, Carlet JM, Masur H, et al Surviving Sepsis Campaign guidelines for management of severe sepsis and septic: shock. Crit Care Med, 2004,30:536-555.
5. Bone RC, Sir Isaac. Newton, sepsis, SIRS, CARS. Crit Care Med. 1996,24:1125-1128.
6. Munford RS, Pugin J. Normal responses to injury prevent systemic-inflammation and can be immunosuppressive. Am J Respir Crit Care Med, 2000,163:316-321. (Pubitemid 32158505)
7. Hotchkiss RS, Swanson PE, Freeman BD, et al. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit Care Med, 1999,27:1230-1251.
8. Fialkow L, Filho LF, Bozzetti MC. Neutrophil apoptosis: a marker of disease severity in sepsis and sepsis-induced acute respiratory distress syndrome. Critical Care, 2006,10:R155.
9. Holchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med, 2003,348:138-150.
10. Pugin J. Immunostimulation is a rational therapeutic strategy in sepsis. Novartis Found Symp, 2007,280:21-27.
11. Garcia-Fernandez N, Lavilla FJ, Rocha E, et al. Haemostatic changes in systemic inflammatory response: syndrome during continuous renal replacement therapy. J Nephrol, 2000,13:282-289. (Pubitemid 30618072)
12. Bellomo R, Ronco C. High-volume haemofiltration in human septic shock. Intensive Care Med, 2001,27:978-986. (Pubitemid 32662478)
13. Claudio Ronco, Ciro Tetta, Filippo Mariano, et al. Interpreting the mechanisms of continous renal replacement therapy in sepsis; the peak concentration hypothesis. Artif Organs, 2003,27:792-780.
14. Awad SS, Swaniker F, Soldes OS, et al. Can the clearance of tumor necrosis factor alpha and interleukin 6 be enhanced using an albumin dialysate hemodiafiltration system? ASAIO J, 1999,45:4749.
15. Notohamiprodjo M, Banayosy A, Kizner L, et al. One year experience wilh MARS-therapy in patients with multiple organ failure in Cardiac: Center Bad Oeyenhausen. Z Gastroenterol, 2001,39(S2):51